{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T01:54:16Z","timestamp":1788314056666,"version":"build-2803163510"},"reference-count":62,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T00:00:00Z","timestamp":1761782400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T00:00:00Z","timestamp":1761782400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100011645","name":"Kaohsiung Medical University Chung-Ho Memorial Hospital","doi-asserted-by":"publisher","award":["KMUH110-0R21, KMUH111-1R15, KMUH112-2R23, KMUH-DK(B)114002-1"],"award-info":[{"award-number":["KMUH110-0R21, KMUH111-1R15, KMUH112-2R23, KMUH-DK(B)114002-1"]}],"id":[{"id":"10.13039\/501100011645","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004663","name":"Ministry of Science and Technology, Taiwan","doi-asserted-by":"publisher","award":["MOST 110-2628-B-037-009, 111-2314-B-037-050-MY2"],"award-info":[{"award-number":["MOST 110-2628-B-037-009, 111-2314-B-037-050-MY2"]}],"id":[{"id":"10.13039\/501100004663","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Kaohsiung Medical University Research Center Grants","award":["(KMU-TC113B04, KMUH-DK(C)113006, KMU-TC113A04"],"award-info":[{"award-number":["(KMU-TC113B04, KMUH-DK(C)113006, KMU-TC113A04"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"DOI":"10.1186\/s12967-025-07252-1","type":"journal-article","created":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T10:04:24Z","timestamp":1761818664000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Targeting lncRNA MALAT1 attenuates lenalidomide resistance via CD38 epigenetic modulation, oxidative stress\u2013mediated cell death, and remodeling of the pro-tumor microenvironment in multiple myeloma"],"prefix":"10.1186","volume":"23","author":[{"given":"Wen-Hsin","family":"Chang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Ting","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsung-Jang","family":"Yeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sin-Hua","family":"Moi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Chang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui-Hua","family":"Hsiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui-Ching","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeng-Shiun","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuh-Ching","family":"Gau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ching-I","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ching-Ping","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chin-Mu","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9884-9429","authenticated-orcid":false,"given":"Shih-Feng","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,30]]},"reference":[{"key":"7252_CR1","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1056\/NEJMra1011442","volume":"364","author":"A Palumbo","year":"2011","unstructured":"Palumbo A, Anderson K. Multiple myeloma. N Engl J Med. 2011;364:1046\u201360.","journal-title":"N Engl J Med"},{"key":"7252_CR2","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1056\/NEJMoa1411321","volume":"372","author":"AK Stewart","year":"2015","unstructured":"Stewart AK, Rajkumar SV, Dimopoulos MA, Masszi T, Spicka I, Oriol A, Hajek R, Rosinol L, Siegel DS, Mihaylov GG, et al. Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. N Engl J Med. 2015;372:142\u201352.","journal-title":"N Engl J Med"},{"key":"7252_CR3","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1056\/NEJMoa1516282","volume":"374","author":"P Moreau","year":"2016","unstructured":"Moreau P, Masszi T, Grzasko N, Bahlis NJ, Hansson M, Pour L, Sandhu I, Ganly P, Baker BW, Jackson SR, et al. Oral Ixazomib, Lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med. 2016;374:1621\u201334.","journal-title":"N Engl J Med"},{"key":"7252_CR4","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1016\/S1470-2045(19)30152-4","volume":"20","author":"PG Richardson","year":"2019","unstructured":"Richardson PG, Oriol A, Beksac M, Liberati AM, Galli M, Schjesvold F, Lindsay J, Weisel K, White D, Facon T, et al. Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with Lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial. Lancet Oncol. 2019;20:781\u201394.","journal-title":"Lancet Oncol"},{"key":"7252_CR5","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1038\/nrclinonc.2016.122","volume":"14","author":"S Manier","year":"2017","unstructured":"Manier S, Salem KZ, Park J, Landau DA, Getz G, Ghobrial IM. Genomic complexity of multiple myeloma and its clinical implications. Nat Rev Clin Oncol. 2017;14:100\u201313.","journal-title":"Nat Rev Clin Oncol"},{"key":"7252_CR6","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1038\/nrc3257","volume":"12","author":"GJ Morgan","year":"2012","unstructured":"Morgan GJ, Walker BA, Davies FE. The genetic architecture of multiple myeloma. Nat Rev Cancer. 2012;12:335\u201348.","journal-title":"Nat Rev Cancer"},{"key":"7252_CR7","doi-asserted-by":"publisher","first-page":"2183","DOI":"10.1158\/0008-5472.CAN-11-2067","volume":"72","author":"JA Fowler","year":"2012","unstructured":"Fowler JA, Mundy GR, Lwin ST, Edwards CM. Bone marrow stromal cells create a permissive microenvironment for myeloma development: a new stromal role for Wnt inhibitor Dkk1. Cancer Res. 2012;72:2183\u20139.","journal-title":"Cancer Res"},{"key":"7252_CR8","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1111\/imr.12233","volume":"263","author":"Y Kawano","year":"2015","unstructured":"Kawano Y, Moschetta M, Manier S, Glavey S, Gorgun GT, Roccaro AM, Anderson KC, Ghobrial IM. Targeting the bone marrow microenvironment in multiple myeloma. Immunol Rev. 2015;263:160\u201372.","journal-title":"Immunol Rev"},{"key":"7252_CR9","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.1038\/leu.2017.138","volume":"31","author":"SK Kumar","year":"2017","unstructured":"Kumar SK, Dimopoulos MA, Kastritis E, Terpos E, Nahi H, Goldschmidt H, Hillengass J, Leleu X, Beksac M, Alsina M, et al. Natural history of relapsed myeloma, refractory to Immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study. Leukemia. 2017;31:2443\u20138.","journal-title":"Leukemia"},{"key":"7252_CR10","doi-asserted-by":"crossref","unstructured":"Cho SF, Xing L, Anderson KC, Tai YT. Promising antigens for the new frontier of targeted immunotherapy in multiple myeloma. Cancers (Basel) 2021;13.","DOI":"10.3390\/cancers13236136"},{"key":"7252_CR11","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1182\/blood-2017-06-740944","volume":"131","author":"N van de Donk","year":"2018","unstructured":"van de Donk N, Richardson PG, Malavasi F. CD38 antibodies in multiple myeloma: back to the future. Blood. 2018;131:13\u201329.","journal-title":"Blood"},{"key":"7252_CR12","doi-asserted-by":"publisher","first-page":"2166","DOI":"10.1182\/blood-2018-05-850727","volume":"132","author":"PL Fedele","year":"2018","unstructured":"Fedele PL, Willis SN, Liao Y, Low MS, Rautela J, Segal DH, Gong JN, Huntington ND, Shi W, Huang DCS, et al. IMiDs prime myeloma cells for daratumumab-mediated cytotoxicity through loss of Ikaros and Aiolos. Blood. 2018;132:2166\u201378.","journal-title":"Blood"},{"key":"7252_CR13","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1038\/s41375-020-0840-y","volume":"35","author":"E Garcia-Guerrero","year":"2021","unstructured":"Garcia-Guerrero E, Gotz R, Doose S, Sauer M, Rodriguez-Gil A, Nerreter T, Kortum KM, Perez-Simon JA, Einsele H, Hudecek M, Danhof S. Upregulation of CD38 expression on multiple myeloma cells by novel HDAC6 inhibitors is a class effect and augments the efficacy of daratumumab. Leukemia. 2021;35:201\u201314.","journal-title":"Leukemia"},{"key":"7252_CR14","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1111\/bjh.15673","volume":"185","author":"A Bat-Erdene","year":"2019","unstructured":"Bat-Erdene A, Nakamura S, Oda A, Iwasa M, Teramachi J, Ashtar M, Harada T, Miki H, Tenshin H, Hiasa M, et al. Class 1 HDAC and HDAC6 Inhibition inversely regulates CD38 induction in myeloma cells via interferon-alpha and ATRA. Br J Haematol. 2019;185:969\u201374.","journal-title":"Br J Haematol"},{"key":"7252_CR15","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1038\/s41375-023-01983-0","volume":"37","author":"D Chemlal","year":"2023","unstructured":"Chemlal D, Varlet E, Machura A, Ovejero S, Requirand G, Robert N, Cartron G, Alaterre E, Bret C, Vincent L, et al. EZH2 targeting induces CD38 upregulation and response to anti-CD38 immunotherapies in multiple myeloma. Leukemia. 2023;37:1925\u20138.","journal-title":"Leukemia"},{"key":"7252_CR16","doi-asserted-by":"publisher","first-page":"2796","DOI":"10.1002\/jcp.30760","volume":"237","author":"F Zeng","year":"2022","unstructured":"Zeng F, Zhang J, Jin X, Liao Q, Chen Z, Luo G, Zhou Y. Effect of CD38 on B-cell function and its role in the diagnosis and treatment of B-cell-related diseases. J Cell Physiol. 2022;237:2796\u2013807.","journal-title":"J Cell Physiol"},{"key":"7252_CR17","doi-asserted-by":"publisher","first-page":"1984","DOI":"10.1097\/JTO.0b013e3182307eac","volume":"6","author":"LH Schmidt","year":"2011","unstructured":"Schmidt LH, Spieker T, Koschmieder S, Schaffers S, Humberg J, Jungen D, Bulk E, Hascher A, Wittmer D, Marra A, et al. The long noncoding MALAT-1 RNA indicates a poor prognosis in non-small cell lung cancer and induces migration and tumor growth. J Thorac Oncol. 2011;6:1984\u201392.","journal-title":"J Thorac Oncol"},{"key":"7252_CR18","doi-asserted-by":"publisher","first-page":"3355","DOI":"10.1007\/s13277-014-2969-7","volume":"36","author":"KX Ma","year":"2015","unstructured":"Ma KX, Wang HJ, Li XR, Li T, Su G, Yang P, Wu JW. Long noncoding RNA MALAT1 associates with the malignant status and poor prognosis in glioma. Tumour Biol. 2015;36:3355\u20139.","journal-title":"Tumour Biol"},{"key":"7252_CR19","first-page":"3174","volume":"7","author":"HT Zheng","year":"2014","unstructured":"Zheng HT, Shi DB, Wang YW, Li XX, Xu Y, Tripathi P, Gu WL, Cai GX, Cai SJ. High expression of LncRNA MALAT1 suggests a biomarker of poor prognosis in colorectal cancer. Int J Clin Exp Pathol. 2014;7:3174\u201381.","journal-title":"Int J Clin Exp Pathol"},{"key":"7252_CR20","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1186\/1471-2407-14-809","volume":"14","author":"SF Cho","year":"2014","unstructured":"Cho SF, Chang YC, Chang CS, Lin SF, Liu YC, Hsiao HH, Chang JG, Liu TC. MALAT1 long non-coding RNA is overexpressed in multiple myeloma and May serve as a marker to predict disease progression. BMC Cancer. 2014;14:809.","journal-title":"BMC Cancer"},{"key":"7252_CR21","doi-asserted-by":"publisher","first-page":"2250","DOI":"10.1038\/s41375-018-0104-2","volume":"32","author":"Y Hu","year":"2018","unstructured":"Hu Y, Lin J, Fang H, Fang J, Li C, Chen W, Liu S, Ondrejka S, Gong Z, Reu F, et al. Targeting the MALAT1\/PARP1\/LIG3 complex induces DNA damage and apoptosis in multiple myeloma. Leukemia. 2018;32:2250\u201362.","journal-title":"Leukemia"},{"key":"7252_CR22","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1007\/s00432-020-03127-8","volume":"146","author":"N Liu","year":"2020","unstructured":"Liu N, Feng S, Li H, Chen X, Bai S, Liu Y. Long non-coding RNA MALAT1 facilitates the tumorigenesis, invasion and Glycolysis of multiple myeloma via miR-1271-5p\/SOX13 axis. J Cancer Res Clin Oncol. 2020;146:367\u201379.","journal-title":"J Cancer Res Clin Oncol"},{"key":"7252_CR23","doi-asserted-by":"publisher","first-page":"101984","DOI":"10.18632\/oncotarget.21957","volume":"8","author":"Y Gu","year":"2017","unstructured":"Gu Y, Xiao X, Yang S. LncRNA MALAT1 acts as an oncogene in multiple myeloma through sponging miR-509-5p to modulate FOXP1 expression. Oncotarget. 2017;8:101984\u201393.","journal-title":"Oncotarget"},{"key":"7252_CR24","doi-asserted-by":"publisher","first-page":"1948","DOI":"10.1038\/s41375-018-0067-3","volume":"32","author":"N Amodio","year":"2018","unstructured":"Amodio N, Stamato MA, Juli G, Morelli E, Fulciniti M, Manzoni M, Taiana E, Agnelli L, Cantafio MEG, Romeo E, et al. Drugging the LncRNA MALAT1 via LNA GapmeR ASO inhibits gene expression of proteasome subunits and triggers anti-multiple myeloma activity. Leukemia. 2018;32:1948\u201357.","journal-title":"Leukemia"},{"key":"7252_CR25","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1186\/s13045-018-0606-4","volume":"11","author":"N Amodio","year":"2018","unstructured":"Amodio N, Raimondi L, Juli G, Stamato MA, Caracciolo D, Tagliaferri P, Tassone P. MALAT1: a druggable long non-coding RNA for targeted anti-cancer approaches. J Hematol Oncol. 2018;11:63.","journal-title":"J Hematol Oncol"},{"key":"7252_CR26","doi-asserted-by":"publisher","first-page":"2509","DOI":"10.1080\/15384101.2019.1652034","volume":"18","author":"Y Sun","year":"2019","unstructured":"Sun Y, Jiang T, Jia Y, Zou J, Wang X, Gu W. LncRNA MALAT1\/miR-181a-5p affects the proliferation and adhesion of myeloma cells via regulation of Hippo-YAP signaling pathway. Cell Cycle. 2019;18:2509\u201323.","journal-title":"Cell Cycle"},{"key":"7252_CR27","doi-asserted-by":"crossref","unstructured":"Tschumper RC, Hoelzinger DB, Walters DK, Davila JI, Osborne CA, Jelinek DF. Stage-specific non-coding RNA expression patterns during in vitro human B cell differentiation into antibody secreting plasma cells. Noncoding RNA 2022;8.","DOI":"10.3390\/ncrna8010015"},{"key":"7252_CR28","doi-asserted-by":"publisher","first-page":"16839","DOI":"10.1038\/s41598-023-44174-8","volume":"13","author":"EM Fernandez-Garnacho","year":"2023","unstructured":"Fernandez-Garnacho EM, Nadeu F, Martin S, Mozas P, Rivero A, Delgado J, Gine E, Lopez-Guillermo A, Duran-Ferrer M, Salaverria I, et al. MALAT1 expression is associated with aggressive behavior in indolent B-cell neoplasms. Sci Rep. 2023;13:16839.","journal-title":"Sci Rep"},{"key":"7252_CR29","doi-asserted-by":"publisher","first-page":"eabq7289","DOI":"10.1126\/sciadv.abq7289","volume":"8","author":"H Miao","year":"2022","unstructured":"Miao H, Wu F, Li Y, Qin C, Zhao Y, Xie M, Dai H, Yao H, Cai H, Wang Q, et al. MALAT1 modulates alternative splicing by cooperating with the splicing factors PTBP1 and PSF. Sci Adv. 2022;8:eabq7289.","journal-title":"Sci Adv"},{"key":"7252_CR30","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1016\/j.molcel.2010.08.011","volume":"39","author":"V Tripathi","year":"2010","unstructured":"Tripathi V, Ellis JD, Shen Z, Song DY, Pan Q, Watt AT, Freier SM, Bennett CF, Sharma A, Bubulya PA, et al. The nuclear-retained noncoding RNA MALAT1 regulates alternative splicing by modulating SR splicing factor phosphorylation. Mol Cell. 2010;39:925\u201338.","journal-title":"Mol Cell"},{"key":"7252_CR31","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1182\/blood-2016-09-738872","volume":"129","author":"S Sebastian","year":"2017","unstructured":"Sebastian S, Zhu YX, Braggio E, Shi CX, Panchabhai SC, Van Wier SA, Ahmann GJ, Chesi M, Bergsagel PL, Stewart AK, Fonseca R. Multiple myeloma cells\u2019 capacity to decompose H(2)O(2) determines Lenalidomide sensitivity. Blood. 2017;129:991\u20131007.","journal-title":"Blood"},{"key":"7252_CR32","doi-asserted-by":"publisher","first-page":"334","DOI":"10.3389\/fphar.2018.00334","volume":"9","author":"Q Li","year":"2018","unstructured":"Li Q, Yue Y, Chen L, Xu C, Wang Y, Du L, Xue X, Liu Q, Wang Y, Fan F. Resveratrol sensitizes Carfilzomib-Induced apoptosis via promoting oxidative stress in multiple myeloma cells. Front Pharmacol. 2018;9:334.","journal-title":"Front Pharmacol"},{"key":"7252_CR33","doi-asserted-by":"crossref","unstructured":"Coan M, Haefliger S, Ounzain S, Johnson R. Targeting and engineering long non-coding RNAs for cancer therapy. Nat Rev Genet. 2024.","DOI":"10.1038\/s41576-024-00693-2"},{"key":"7252_CR34","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1038\/s41573-021-00219-z","volume":"20","author":"M Winkle","year":"2021","unstructured":"Winkle M, El-Daly SM, Fabbri M, Calin GA. Noncoding RNA therapeutics - challenges and potential solutions. Nat Rev Drug Discov. 2021;20:629\u201351.","journal-title":"Nat Rev Drug Discov"},{"key":"7252_CR35","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1186\/s13046-021-02193-1","volume":"40","author":"R Cuciniello","year":"2021","unstructured":"Cuciniello R, Filosa S, Crispi S. Novel approaches in cancer treatment: preclinical and clinical development of small non-coding RNA therapeutics. J Exp Clin Cancer Res. 2021;40:383.","journal-title":"J Exp Clin Cancer Res"},{"key":"7252_CR36","first-page":"1354","volume":"9","author":"MC Jiang","year":"2019","unstructured":"Jiang MC, Ni JJ, Cui WY, Wang BY, Zhuo W. Emerging roles of LncRNA in cancer and therapeutic opportunities. Am J Cancer Res. 2019;9:1354\u201366.","journal-title":"Am J Cancer Res"},{"key":"7252_CR37","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1016\/j.omtn.2020.07.005","volume":"21","author":"D Fu","year":"2020","unstructured":"Fu D, Shi Y, Liu JB, Wu TM, Jia CY, Yang HQ, Zhang DD, Yang XL, Wang HM, Ma YS. Targeting long Non-coding RNA to therapeutically regulate gene expression in cancer. Mol Ther Nucleic Acids. 2020;21:712\u201324.","journal-title":"Mol Ther Nucleic Acids"},{"key":"7252_CR38","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.molmed.2018.01.001","volume":"24","author":"G Arun","year":"2018","unstructured":"Arun G, Diermeier SD, Spector DL. Therapeutic targeting of long Non-Coding RNAs in cancer. Trends Mol Med. 2018;24:257\u201377.","journal-title":"Trends Mol Med"},{"key":"7252_CR39","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1038\/s41467-025-56913-8","volume":"16","author":"NK Leclair","year":"2025","unstructured":"Leclair NK, Brugiolo M, Park S, Devoucoux M, Urbanski L, Angarola BL, Yurieva M, Anczukow O. Antisense oligonucleotide-mediated TRA2beta poison exon inclusion induces the expression of a LncRNA with anti-tumor effects. Nat Commun. 2025;16:1670.","journal-title":"Nat Commun"},{"key":"7252_CR40","doi-asserted-by":"publisher","first-page":"217192","DOI":"10.1016\/j.canlet.2024.217192","volume":"602","author":"H Wu","year":"2024","unstructured":"Wu H, Sun C, Cao W, Teng Q, Ma X, Schioth HB, Dong R, Zhang Q, Kong B. Blockade of the lncRNA-PART1-PHB2 axis confers resistance to PARP inhibitor and promotes cellular senescence in ovarian cancer. Cancer Lett. 2024;602:217192.","journal-title":"Cancer Lett"},{"key":"7252_CR41","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1186\/s12943-020-01217-2","volume":"19","author":"J Chen","year":"2020","unstructured":"Chen J, Liu A, Wang Z, Wang B, Chai X, Lu W, Cao T, Li R, Wu M, Lu Z, et al. LINC00173.v1 promotes angiogenesis and progression of lung squamous cell carcinoma by sponging miR-511-5p to regulate VEGFA expression. Mol Cancer. 2020;19:98.","journal-title":"Mol Cancer"},{"key":"7252_CR42","doi-asserted-by":"publisher","first-page":"314ra185","DOI":"10.1126\/scitranslmed.aac5272","volume":"7","author":"D Hong","year":"2015","unstructured":"Hong D, Kurzrock R, Kim Y, Woessner R, Younes A, Nemunaitis J, Fowler N, Zhou T, Schmidt J, Jo M, et al. AZD9150, a next-generation antisense oligonucleotide inhibitor of STAT3 with early evidence of clinical activity in lymphoma and lung cancer. Sci Transl Med. 2015;7:314ra185.","journal-title":"Sci Transl Med"},{"key":"7252_CR43","doi-asserted-by":"publisher","first-page":"3301","DOI":"10.1158\/1078-0432.CCR-22-2483","volume":"29","author":"M Roschewski","year":"2023","unstructured":"Roschewski M, Patel MR, Reagan PM, Saba NS, Collins GP, Arkenau HT, de Vos S, Nuttall B, Acar M, Burke K, et al. Phase I study of acalabrutinib plus Danvatirsen (AZD9150) in Relapsed\/Refractory diffuse large B-Cell lymphoma including Circulating tumor DNA biomarker assessment. Clin Cancer Res. 2023;29:3301\u201312.","journal-title":"Clin Cancer Res"},{"key":"7252_CR44","doi-asserted-by":"publisher","first-page":"e136","DOI":"10.1016\/S2352-3026(18)30021-8","volume":"5","author":"M Ohanian","year":"2018","unstructured":"Ohanian M, Tari Ashizawa A, Garcia-Manero G, Pemmaraju N, Kadia T, Jabbour E, Ravandi F, Borthakur G, Andreeff M, Konopleva M, et al. Liposomal Grb2 antisense oligodeoxynucleotide (BP1001) in patients with refractory or relapsed haematological malignancies: a single-centre, open-label, dose-escalation, phase 1\/1b trial. Lancet Haematol. 2018;5:e136\u201346.","journal-title":"Lancet Haematol"},{"key":"7252_CR45","doi-asserted-by":"publisher","first-page":"102256","DOI":"10.1016\/j.omtn.2024.102256","volume":"35","author":"B Dume","year":"2024","unstructured":"Dume B, Licarete E, Banciu M. Advancing cancer treatments: the role of oligonucleotide-based therapies in driving progress. Mol Ther Nucleic Acids. 2024;35:102256.","journal-title":"Mol Ther Nucleic Acids"},{"key":"7252_CR46","doi-asserted-by":"publisher","first-page":"1840","DOI":"10.4049\/jimmunol.1003032","volume":"186","author":"M de Weers","year":"2011","unstructured":"de Weers M, Tai YT, van der Veer MS, Bakker JM, Vink T, Jacobs DC, Oomen LA, Peipp M, Valerius T, Slootstra JW, et al. Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors. J Immunol. 2011;186:1840\u20138.","journal-title":"J Immunol"},{"key":"7252_CR47","doi-asserted-by":"publisher","first-page":"4574","DOI":"10.1158\/1078-0432.CCR-14-0695","volume":"20","author":"J Deckert","year":"2014","unstructured":"Deckert J, Wetzel MC, Bartle LM, Skaletskaya A, Goldmacher VS, Vallee F, Zhou-Liu Q, Ferrari P, Pouzieux S, Lahoute C, et al. SAR650984, a novel humanized CD38-targeting antibody, demonstrates potent antitumor activity in models of multiple myeloma and other CD38\u2009+\u2009hematologic malignancies. Clin Cancer Res. 2014;20:4574\u201383.","journal-title":"Clin Cancer Res"},{"key":"7252_CR48","doi-asserted-by":"publisher","first-page":"2039","DOI":"10.1038\/leu.2015.123","volume":"29","author":"IS Nijhof","year":"2015","unstructured":"Nijhof IS, Groen RW, Lokhorst HM, van Kessel B, Bloem AC, van Velzen J, de Jong-Korlaar R, Yuan H, Noort WA, Klein SK, et al. Upregulation of CD38 expression on multiple myeloma cells by all-trans retinoic acid improves the efficacy of daratumumab. Leukemia. 2015;29:2039\u201349.","journal-title":"Leukemia"},{"key":"7252_CR49","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1182\/blood-2015-12-687749","volume":"128","author":"J Krejcik","year":"2016","unstructured":"Krejcik J, Casneuf T, Nijhof IS, Verbist B, Bald J, Plesner T, Syed K, Liu K, van de Donk NW, Weiss BM, et al. Daratumumab depletes CD38\u2009+\u2009immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma. Blood. 2016;128:384\u201394.","journal-title":"Blood"},{"key":"7252_CR50","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1186\/s40425-019-0719-5","volume":"7","author":"B Mastelic-Gavillet","year":"2019","unstructured":"Mastelic-Gavillet B, Navarro Rodrigo B, Decombaz L, Wang H, Ercolano G, Ahmed R, Lozano LE, Ianaro A, Derre L, Valerio M, et al. Adenosine mediates functional and metabolic suppression of peripheral and tumor-infiltrating CD8(+) T cells. J Immunother Cancer. 2019;7:257.","journal-title":"J Immunother Cancer"},{"key":"7252_CR51","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/j.ccell.2016.06.025","volume":"30","author":"A Young","year":"2016","unstructured":"Young A, Ngiow SF, Barkauskas DS, Sult E, Hay C, Blake SJ, Huang Q, Liu J, Takeda K, Teng MWL, et al. Co-inhibition of CD73 and A2AR adenosine signaling improves Anti-tumor immune responses. Cancer Cell. 2016;30:391\u2013403.","journal-title":"Cancer Cell"},{"key":"7252_CR52","doi-asserted-by":"publisher","first-page":"760","DOI":"10.3389\/fimmu.2019.00760","volume":"10","author":"AL Horenstein","year":"2019","unstructured":"Horenstein AL, Bracci C, Morandi F, Malavasi F. CD38 in adenosinergic pathways and metabolic Re-programming in human multiple myeloma cells: In-tandem insights from basic science to therapy. Front Immunol. 2019;10:760.","journal-title":"Front Immunol"},{"key":"7252_CR53","doi-asserted-by":"publisher","first-page":"e1458809","DOI":"10.1080\/2162402X.2018.1458809","volume":"7","author":"F Morandi","year":"2018","unstructured":"Morandi F, Marimpietri D, Horenstein AL, Bolzoni M, Toscani D, Costa F, Castella B, Faini AC, Massaia M, Pistoia V, et al. Microvesicles released from multiple myeloma cells are equipped with ectoenzymes belonging to canonical and non-canonical adenosinergic pathways and produce adenosine from ATP and NAD(). Oncoimmunology. 2018;7:e1458809.","journal-title":"Oncoimmunology"},{"key":"7252_CR54","doi-asserted-by":"crossref","unstructured":"Plesner T, van de Donk N, Richardson PG. Controversy in the Use of CD38 antibody for treatment of myeloma: is high CD38 expression good or bad? Cells. 2020;9.","DOI":"10.3390\/cells9020378"},{"key":"7252_CR55","doi-asserted-by":"publisher","first-page":"2482","DOI":"10.1158\/1078-0432.CCR-17-3070","volume":"24","author":"TM Ashton","year":"2018","unstructured":"Ashton TM, McKenna WG, Kunz-Schughart LA, Higgins GS. Oxidative phosphorylation as an emerging target in cancer therapy. Clin Cancer Res. 2018;24:2482\u201390.","journal-title":"Clin Cancer Res"},{"key":"7252_CR56","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1016\/j.cmet.2017.10.013","volume":"26","author":"C Bosc","year":"2017","unstructured":"Bosc C, Selak MA, Sarry JE. Resistance is futile: targeting mitochondrial energetics and metabolism to overcome drug resistance in cancer treatment. Cell Metab. 2017;26:705\u20137.","journal-title":"Cell Metab"},{"key":"7252_CR57","doi-asserted-by":"crossref","unstructured":"Bloedjes TA, de Wilde G, Guikema JEJ. Metabolic effects of recurrent genetic aberrations in multiple myeloma. Cancers (Basel) 2021;13.","DOI":"10.3390\/cancers13030396"},{"key":"7252_CR58","doi-asserted-by":"publisher","first-page":"2285","DOI":"10.1158\/0008-5472.CAN-18-0773","volume":"79","author":"CR Marlein","year":"2019","unstructured":"Marlein CR, Piddock RE, Mistry JJ, Zaitseva L, Hellmich C, Horton RH, Zhou Z, Auger MJ, Bowles KM, Rushworth SA. CD38-Driven mitochondrial trafficking promotes bioenergetic plasticity in multiple myeloma. Cancer Res. 2019;79:2285\u201397.","journal-title":"Cancer Res"},{"key":"7252_CR59","doi-asserted-by":"crossref","unstructured":"Bebnowska D, Hrynkiewicz R, Grywalska E, Pasiarski M, Sosnowska-Pasiarska B, Smarz-Widelska I, Gozdz S, Rolinski J, Niedzwiedzka-Rystwej P. Immunological prognostic factors in multiple myeloma. Int J Mol Sci. 2021;22.","DOI":"10.3390\/ijms22073587"},{"key":"7252_CR60","doi-asserted-by":"crossref","unstructured":"Mielnik M, Szudy-Szczyrek A, Homa-Mlak I, Mlak R, Podgajna-Mielnik M, Goracy A, Malecka-Massalska T, Hus M. The clinical relevance of selected cytokines in newly diagnosed multiple myeloma patients. Biomedicines. 2023;11.","DOI":"10.3390\/biomedicines11113012"},{"key":"7252_CR61","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1038\/s41573-020-0075-7","volume":"19","author":"TC Roberts","year":"2020","unstructured":"Roberts TC, Langer R, Wood MJA. Advances in oligonucleotide drug delivery. Nat Rev Drug Discov. 2020;19:673\u201394.","journal-title":"Nat Rev Drug Discov"},{"key":"7252_CR62","doi-asserted-by":"publisher","first-page":"104858","DOI":"10.1016\/j.critrevonc.2025.104858","volume":"215","author":"Q Meng","year":"2025","unstructured":"Meng Q, Yang M, Xing F, Xie Z, Hao Y, Jiang P, Xiao B. Antibody-oligonucleotide conjugates in cancer therapy: potential and promise. Crit Rev Oncol Hematol. 2025;215:104858.","journal-title":"Crit Rev Oncol Hematol"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-025-07252-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-025-07252-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-025-07252-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T11:04:08Z","timestamp":1761822248000},"score":1,"resource":{"primary":{"URL":"https:\/\/translational-medicine.biomedcentral.com\/articles\/10.1186\/s12967-025-07252-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,30]]},"references-count":62,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["7252"],"URL":"https:\/\/doi.org\/10.1186\/s12967-025-07252-1","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,30]]},"assertion":[{"value":"31 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"1199"}}